Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Management of Post-Induction Hypotension in Emergency Abdominal Surgery
NCT07259655 · Hopital Charles Nicolle · PHASE4 · terminated · last registry update 2025-12-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “the investigators collected the necessary sample size for the internal validity of the study” | – | Registry record, Hopital Charles Nicolle |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-28Also stopped (terminated): Algemeen Ziekenhuis Maria Middelares, Plasma-lyte (static group) + Norepinephrine (static group) (NCT06080178)
- 2026-10-14Also stopped (terminated): Yale University, Phenylephrine + Norepinephrine (NCT04218773)
- 2026-10-09Also stopped (suspended): Ergun Y. Uc, Terazosin 5 MG + Placebo (NCT07464028)
- 2026-10-08Results posted on the registry: Opus Genetics, Inc, Phentolamine Mesylate Ophthalmic Solution 1.0% + Phentolamine Mesylate Ophthalmic Solution 0.5% (NCT01703559)
- 2026-10-07Also stopped (withdrawn): Nandakumar Narayanan, Terazosin Hydrochloride (NCT07288450)
- 2026-10-05Results posted on the registry: Ankara City Hospital Bilkent, Sevoflurane (Volatile Anesthetic) + Propofol 1% (NCT07092046)
- 2026-09-21Also stopped (withdrawn): University Ghent, a drug against ADRA1A (NCT06810674)
- 2026-08-18Results posted on the registry: Opus Genetics, Inc, phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist + Placebo (NCT06349759)
- 2026-08-17Results posted on the registry: Opus Genetics, Inc, 0.75% phentolamine ophthalmic solution + Placebo (NCT06542497)
- 2026-04-27Results posted on the registry: University of Pennsylvania, Phentolamine + Propranolol (NCT03079921)
- 2025-12-23Phase 3 first posted: Ain Shams University, Balanced anesthesia + Lidocaine spray (NCT07299630)
- 2025-12-17Results posted on the registry: University of Edinburgh, a drug against ADRA1A (NCT04614168)
- 2025-10-03Phase 3 first posted: University College, London, Placebo + Telmisartan (NCT07207057)
- 2025-08-26Phase 3 first posted: Opus Genetics, Inc, 0.75% Phentolamine Ophthalmic Solution + Placebo (NCT07140783)
- 2025-08-15Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., Cabergoline tablets + Bromocriptine mesylate tablets (NCT07124221)
- 2025-08-13Also stopped (suspended): Charite University, Berlin, Germany, Clonidine + Doxazosin (NCT05360953)
- 2025-07-20Phase 3 first posted: Institute of Liver and Biliary Sciences, India, Umbilical cord Mesenchymal stem cell + Steroid (NCT07075315)
- 2025-07-17Results posted on the registry: Laboratorios Sophia S.A de C.V., Naphazoline / Hypromellose Ophthalmic (NCT05470868)
- 2025-06-13Phase 3 first posted: Universitas Indonesia, Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam (NCT07019805)
- 2025-06-03Results posted on the registry: Opus Genetics, Inc, Phentolamine Opthalmic Solution 0.75% + Low dose pilocarpine (NCT05646719)
- 2025-05-23Also stopped (withdrawn): University of Colorado, Denver, Prazosin + Placebos (NCT03997864)
- 2025-05-13Phase 3 first posted: Penang Hospital, Malaysia, Terazosin + Tamsulosin (NCT06966804)
- 2025-04-11Results posted on the registry: University of California, San Diego, amisulpride + bromocriptine (NCT04128683)
- 2025-03-20Phase 3 first posted: Jagiellonian University, noradrenaline infusion for management blood pressure + standard blood pressure management (NCT06885268)
- 2025-03-07Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, PPA Intervention (NCT06863558)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision